Sarepta shares buoyed by pledge to seek an early swift review for Duchenne gene therapy

[cafead]

via Sarepta Therapeutics’ shares saw a nice boost early Friday morning as the biotech declared its intent to seek an early accelerated approval for the Roche-partnered Duchenne muscular dystrophy (DMD) gene transfer therapy SRP-9001.

article source